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Abstract
Background: Locally recurrent non-small cell lung cancer (NSCLC) poses a great challenge to physicians. This study
aimed to explore the efficacy and safety of the combination of brachytherapy and docetaxel and cisplatin for the
treatment of locally recurrent stage III NSCLC.
Methods: Fifty two patients with locally recurrent stage III NSCLC after concurrent chemoradiotherapy were
randomly divided into two groups (n = 26). The patients in experimental group were treated with implantation of
radioactive 125I seeds and DP regimen (docetaxel 60 mg/m2/cisplatin 75 mg/m2). Patients in control group received
DP chemotherapy. The local control rate (LCR), progression-free survival (PFS), and overall response rate (ORR) were
defined according to the Response Evaluation Criteria in Solid Tumors (RECIST).
Results: With a median follow-up time of 11 months, PFS and LCR was 8 months (95 % CI: 6.99–9.01 months) vs.
5.5 months (95 % CI: 4.43–6.57 months) (P < 0.05) and 10 months (95 % CI: 8.72–11.28 months) vs. 6.2 months
(95 % CI: 5.27–7.13 months) (P < 0.05) in the experimental and control groups, respectively. The ORR did not differ
between treatment groups and was noted to be 69.2 % and 57.7 %, respectively (P >0.05). There was no occurrence
of severe complications in experimental and control groups.
Conclusion: The combination of 125I brachytherapy and second-line chemotherapy is superior to chemotherapy alone
and is an effective and safe therapy for this disease.
Trial registration number: ChiCTR-IOR-15006560
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Background
Lung cancer is the leading cause of malignant tumor
death. Non-small cell lung cancer (NSCLC) accounts for
80–85 % of lung cancers. For advanced inoperable
NSCLC, combined chemoradiotherapy is considered as
the standard first-line treatment [1]. Phase III clinical tri-
als have demonstrated that docetaxel is an effective
therapeutic agent for recurrent NSCLC after first-line
treatment. Nevertheless, for the patients who are treated
with docetaxel-based second-line therapy, their overall
survival (OS) is usually short and prognosis is poor [2].
Treatment of locally recurrent NSCLC after first-line
concurrent chemoradiotherapy poses a great challenge
to physicians [3]. Although chemoradiotherapy can be
considered as an option for subsequent treatment, its
application is strictly limited due to the normal tissue tol-
erance dose of radiation and the development of severe
complications, including chronic basic pulmonary diseases
(e.g. chronic obstructive emphysema), radiation pneumon-
itis, radiation esophagitis, and tracheal necrosis [4].
Currently, implantation of iodine-125 (125I) seeds is a
treatment option for interstitial brachytherapy in lung
cancer [5]. The implanted 125I seeds can generate a high
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dose (140–160 Gy) within target tumor volumes to con-
tinuously destroy tumor cells, while the surrounding
non-neoplastic tissues only receive a very low dose and
subject to little damage. In addition, the low radiation
dose rate can induce the reoxygenation and increased
blood flow of hypoxic tumor volumes, thus producing
radiation-induced bystander effect to kill tumor cells
that can overcome the inhomogeneous distribution of
radiation dose [6, 7]. Percutaneous CT-guided 125I seed
permanent implantation can decrease the local recur-
rence in the treatment of high-risk stage I NSCLC with
less tissue injury and few complications [8]. 125I seed
implantation decrease the local recurrence, especially in
those with a positive cytology at the staple line [9].
Therefore, we hypothesized that the combination of 125I
brachytherapy and second-line chemotherapy may be
ideal for the treatment of locally recurrent stage III non-
small cell lung cancer after first-line therapy. Neverthe-
less, this combined therapy is uncommonly used and its
efficacy and safety remain unclear. In this study we per-
formed a systematic assessment on the clinical efficacy
of the combination of brachytherapy with radioactive
iodine-125 (125I) seeds and chemotherapy for the treat-
ment of locally recurrent stage III NSCLC.
Methods
Patient selection and inclusion
Inclusion criteria were as follows: patients with locally
recurrent stage III NSCLC within one year after receiv-
ing concurrent chemoradiotherapy; time of survival was
estimated to be longer than three months; tumor diam-
eter was less than 6 cm; no severe liver insufficiency or
renal insufficiency, heart diseases, diabetes, coagulation
dysfunction, and other chronic diseases; no severer
chronic obstructive pulmonary diseases; the Eastern Co-
operative Oncology Group (ECOG) score was no more
than 2; tumor lesion was suitable for brachytherapy, as
the location and size of the lesion were confirmed by
chest CT scanning; patients intended to receive the
treatments; patients did not receive any radiotherapy
and chemotherapy within 3 months of this study. Local
recurrence was defined as a 20 % increase in the volume
of primary tumor mass from the point of maximum
tumor regression in the lung without lymph node metas-
tasis. All patients were evaluated by the investigators of
this study (including the oncologists, surgical specialists,
and radiologists of Huai’an First People’s Hospital Affili-
ated to Nanjing Medical University) and confirmed to be
able to receive the second-line chemotherapy by pacli-
taxel (135 mg/m2, at day 1) plus cisplatin (75 mg/m2, at
day 2) and CT-guided radioactive 125I seed implantation.
Based on pathological conformation, 52 patients with
locally recurrent lung cancer within 3–12 months after
receiving concurrent chemoradiotherapy were included
in this study. Prior to the procedure, all patients received
multiple imaging examinations including chest CT,
abdominal CT or magnatic resonance imaging (MRI),
cranial MRI, and bone emission computed tomography
(ECT), blood routine examination, blood coagulation
tests, hepatic and renal function tests, pulmonary func-
tion tests, and electrocardiogram (ECG). Tumor staging
was according to American Joint Committee on Cancer
(AJCC) staging manual (7th edition). All patients were
previously treated by 6- or 15-MV X-ray beams pro-
duced by Siemens ONCOR Expression Linear Acceler-
ator (Siemens AG, Muenchen, Germany). The dose was
2 Gy once daily, 5 times a week, for 6–7 weeks. The
total radiation dose received was 66–70 Gy. The concur-
rent chemotherapy was paclitaxel (135 mg/m2, at day 1)
plus cisplatin (75 mg/m2, at day 2), which was intraven-
ously infused prior to radiotherapy and repeated after
four weeks, for four cycles. The median time to recur-
rence was 7.9 months (range: 5.5–11.2 months). The
study protocols were approved by Ethics Committee of
Huai’an First People’s Hospital Affiliated to Nanjing
Medical University and all patients gave signed informed
consent.
Study design
This was a prospective study (Trial registration number
ChiCTR-IOR-15006560). The 52 patients were divided
into two groups using computer-produced digital ran-
dom method: experimental group, the patients received
the combined therapy of 125I seed implantation, doce-
taxel (60 mg/m2 at day 1), and cisplatin (75 mg/m2 at
day 2); control group, the patients received the combin-
ation of docetaxel (60 mg/m2 at day 1) and cisplatin
(75 mg/m2 at day 2). Chemotherapy cycle length was
three weeks and planned duration of chemotherapy was
four cycles. Primary endpoints were progression-free
survival and time of local control. CT/PET scans were
not available during the years of the study due to eco-
nomic reasons.
CT-guided implantation of 125I seeds
Sixty-four slice spiral CT scanner (SIEMENS Somatom
Sensation 64 CT Scanner) was provided by Siemens. Radio-
therapy treatment planning system (TPS) HGGR-2000 was
provided by Zhuhai Hokai Medical Instruments Co., Ltd
(Zhuhai, China). Implantation needle (18 Gauge), implant-
ation gun, and 125I seeds were provided by Ningbo Jun’an
Pharmaceutical Technology Co., Ltd (Ningbo, China). The
planning target volume (PTV) of lung tumor was defined
and outlined after CT scan. Radiotherapy treatment plan
for each patient was optimized according to the safety
margin around the tumor volume or normal tissues and
the radiation dose and radioactivity of 125I seeds. The 125I
radioactive seeds used in this study had a length of
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4.5 mm and a diameter of 0.8 mm, with an average energy
of 27–32 keV, a half life of 59.6 days, and a tissue pene-
tration range of 1.7 cm. The initial dose rate was 7 cGy/h
prescribed to 1 cm depth, and the prescription dose was
90–110 Gy. The ideal position for radioactive seed im-
plantation was determined based on pre-operative TPS
and physical condition of patients. The correct entry
point, the direction of needle advancement, and the space
between implanted 125I seeds were determined under CT-
guidance. After intramuscular injection of 10 mg diaze-
pam and 100 mg pethidine hydrochloride, 125I seeds were
implanted in the tissues via needles. The space between
the implanted seeds was 1.5 cm. The activity of 125I seeds
was 2.22–2.59 x 107 Bq. Post-operative chest CT examin-
ation was performed to monitor the implantation-related
complications (e.g. pulmonary hemorrhage, pneumotho-
rax, or migration of radioactive seeds). Acquired CT
images were then transferred to TPS for the dosimetry
evaluation of implanted 125I seeds. The evaluation indica-
tors included the tumor matched peripheral dose (MPD)
and the dose that 90 % of the target volume received
(D90). Postoperative monitoring of vital signs was
conducted for all patients. Antibiotic prophylaxis was
used to prevent post-operative infection. One week
after the implatation, hemogram was examined to detect
any complications.
Evaluation of efficacy and safety
The efficacy was evaluated three months after interstitial
permanent implantation of 125I seeds. Tumor response
was evaluated based on imaging findings in accordance
with the Response Evaluation Criteria in Solid Tumors
(RECIST) criteria: complete response (CR), complete
disappearance of target lesions (negative findings or only
funicular shadows on imaging evaluation); partial re-
sponse (PR), at least a 30 % decrease in the sum of the
longest diameters of target lesions; progressive disease
(PD), at least a 20 % increase in the sum of the longest
diameters of target lesions or the appearance of one or
more new lesions; stable disease (SD), neither sufficient
shrinkage to qualify for PR nor sufficient increase to
qualify for PD. The response rate (RR) of treatment was
calculated using the following formula: RR = (CR + PR)/
total number of patients × 100 %. The acute and late
radiation toxicities were assessed according to toxicity cri-
teria of the Radiation Therapy Oncology Group (RTOG)
and the European Organization for Research and Treat-
ment of Cancer (EORTC) [10].
Follow-up
All patients were followed up from January 2006 until
the time of local recurrence and disease progression.
The range of follow-up was 4.5–24 months, with a me-
dian of 11 months.
Statistical analysis
Statistical analysis was performed using SPSS 13.0 soft-
ware. Kaplan-Meier survival curve method was used to
estimate local control rate and PFS. The log-rank test
was used to compare the difference between two
treatment groups. Fisher’s exact test was used to as-
sess the difference in CR rate and short-term efficacy be-
tween both groups. P < 0.05 was considered statistically
significant.
Results
Of 26 patients who received 125I brachytherapy, 15 were
male and 11 were female. The median age was 62 years
(age range: 48–72 years). Nine patients had squamous
cell carcinoma, 16 had adenocarcinoma, and one had
large cell carcinoma. Fourteen patients had stage IIIa
NSCLC and 12 had stage IIIb NSCLC (Table 1). The
number of implanted 125I seeds in these patients ranged
between 15 and 92, with a median number of 34. The
immediate post-operative CT scan demonstrated that
the tumor MPD in these patients ranged between 90.2
and 130.6 Gy, with a median dose of 110.0 Gy. The
D90 was 103.6–148.2 Gy in these patients, with a me-
dian dose of 128.9 Gy (Table 2). After brachytherapy,
re-implantation of 125I seeds was required in one patient.
Three patients had mild pneumothorax, two patients had
hemoptysis, two had low-grade fever, and seed migration
was observed in one patient. The patients with mild
pneumothorax received conservative therapy and finally
recovered completely. Another patient with grade III
Table 1 Baseline characteristics of patients enrolled in this
study





Gender Male 15 17 0.776
Female 11 9
Stage IIIA 14 16 0.779
IIIB 12 10

















3 cm 16 20 0.368
3–6 cm 10 6
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radiation pneumonitis obtained symptom relief after
drug therapy (Table 3). There were no grade 4/5 com-
plications in both experimental and control groups. The
CT scan images of one representative patient were shown
in Fig. 1.
For patients who received the combined therapy of
125I brachytherapy and DP chemotherapy, the time of
local control was between 4.5 and 24 months, with a
median of 10 months (95 % CI: 8.72–11.28 months). Of
the patients in this cohort, three achieved progression
free of disease after 24-month follow-up. The median
PFS was 8 months (95 % CI: 6.99–9.01 months). The
range of PFS was 3–24 months. Three months after 125I
brachytherapy, the overall response rate (ORR) was
69.2 % (18/26). The rates of CR, PR, SD, and PD in this
cohort were 38.5 % (10/26), 30.8 % (8/26), 23.8 % (6/26),
and 7.7 % (2/26), respectively. For the control group, the
time of local control was 3–15 months, with a median of
6.2 months (95 % CI: 5.27–7.13 months). The median
PFS was 5.5 months (95 % CI: 4.43–6.57 months). The
range of PFS was 3–10 months. The overall response
rate was 57.7 % (15/26). The rates of CR, PR, SD, and
PD in this cohort were 7.7 % (2/26), 50.0 % (13/26),
30.8 % (8/26), and 11.5 % (3/26), respectively.
There was no significant difference in ORR between
the experimental group and the control group (χ2 = 0.75,
P = 0.57 > 0.05). For the rate of CR, the time of local
control, and PFS, there was significant difference be-
tween both groups (χ2 = 7.43, P = 0.02 < 0.05 for the rate
of CR; χ2 = 8.59, P = 0.003 < 0.01 for the time of local
control; χ2 = 4.7, P = 0.04 < 0.05 for PFS) (Figs. 2 and 3).
The median time of local control in the experimental
group and the control group was 10 and 6.2 months,
respectively. There was significant difference in this
outcome between two groups (P < 0.05). For PFS, the
experimental group had a median of 8.0 months, which
was significantly longer than that in the control group
(5.5 months) (P < 0.05).
Discussion
Lung cancer is the most common cancer worldwide.
The majority of lung cancer patients are not diagnosed
until the disease is at the relatively late stage. The pa-
tients with advanced lung cancer usually have a very
short survival. Currently, lung cancer therapies are not
satisfactory in their efficacy of improving the survival of
patients. Clinical studies have proven that concurrent
chemoradiotherapy is a standard treatment for locally
Table 2 Parameters of brachytherapy with radioactive 125I seeds
Parameters Median value Range
MPD (Gy) 110.0 90.2–130.6
D90 (Gy) 128.9 103.6–148.2
Number of seeds implanted 34 15–92
Activity (mCi per seed) 0.6 0.6–0.9
Dose rate (Gy/h) 0.07 0.05–0.09






Grade 4/5 complications 0 0
Mild complications
Mild pneumothorax 3 3
Hemoptysi 2 3
Low-grade fever (38.5 C) 2 5
Radiation pneumonitis 1 0
Seed migration 1 0
Local skin erythema 0 1
No complications 17 14
Fig. 1 The reccurent tumot lesions in a representative patient who
previsouly received concurrent chemoradiotherapy (a). After the
combination of 125I brachytherapy and DP regimen, complete
disappearance of target lesions was achieved (b)
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advanced NSCLC, which can provide a 2-year survival
rate of 39.7 %, a median OS of up to 22 months, and a
median PFS of 17 months [11]. However, for the patients
with locally recurrent stage III NSCLC (stage IIIA and
III B) after concurrent chemoradiotherapy, the treatment
mainly depends on second-line chemotherapy or mo-
lecular targeted therapy, which can provide a median OS
of 11.7–12.2 months, a median PFS of 2–3 months, and
a one-year survival rate of 30 % [12]. However, these
therapies are not yet considered as the standard treatment
for locally recurrent stage III NSCLC after concurrent
chemoradiotherapy, further investigations are required to
explore and optimize possible treatment regimens.
Development of computerized three-dimensional TPS
has attracted more attention of physicians on CT-guide
brachytherapy with radioactive seeds for treating malig-
nant tumors [13]. The 125I radioactive seeds have an
effective emission range of 1.7 cm in tissue. During the
half-life of 125I radioactive seeds (59.6 days), tumor cells
at different phases of the cell cycle can be destroyed by
the gamma-rays emitted from the radioactive seed.
Previous studies have shown that the low radiation dose
rate could increase the sensitivity of hypoxic tumor cells
to radioactive rays and produce radiation-induced by-
stander effect to kill tumor cells [7, 14]. In vitro studies
have shown that 125I radioactive seeds up-regulated
apoptosis-related genes, and regulated cell cycle and
apoptosis of tumor cells [15]. Taken together, 125I radio-
active seeds have the advantages including high con-
formality index and producing high dose in target
volumes and low radioactive exposure to surrounding
normal tissues, thus having great potential in the treat-
ment of locally recurrent tumors [16].
Currently, brachytherapy with 125I seeds are widely used
in clinic for the treatment of recurrent and metastatic
prostate tumor and head and neck tumors [17–19]. How-
ever, this therapy has been rarely reported for treating
patients with locally recurrent NSCLC. In this study we
investigated the clinical efficacy of the combination of 125I
brachytherapy and chemotherapy in the patients with
locally recurrent stage III NSCLC after concurrent chemo-
radiotherapy. Our results demonstrated that this com-
bined therapy achieved satisfactory efficacy compared
with chemotherapy alone. For the combined therapy, the
median time of local control was 10 months. Three pa-
tients achieved progression free of disease after 24-month
follow-up. The median PFS was 8 months. Three months
after 125I brachytherapy, ORR was 69.2 % (18/26). The
rates of CR and PR were 38.5 % (10/26) and 30.8 % (8/26),
respectively, which were significantly higher than those in
the control group. Recent studies have indicated that local
disease control rate is an important independent prognos-
tic factor for the OS of patients with locally advanced lung
cancer [20]. In the present study, 125I radioactive seeds
were shown to have a good local tumor control. For three
patients with well differentiated adenocarcinoma (tumor
diameter < 3 cm with single metastatic lesion), the
time of local control was longer than two years, sug-
gesting that the degree of tumor differentiation, growth
rate, and tumor size could affect the local efficacy in
NSCLC patients.
Furthermiore, there was no occurrence of severe com-
plications during the study, indicating that combined
therapy of 125I brachytherapy and DP regimen is effect-
ive and safe for the treatment of locally recurrent stage
III NSCLC after concurrent chemoradiotherapy. Further
large-sale studies are needed to verify the potential of
the combination of 125I brachytherapy and second-line
chemotherapy for treament of locally recurrent stage III
NSCLC.
Conclusions
The combination of 125I brachytherapy and second-line
chemotherapy is superior to chemotherapy alone and is
an effective and safe therapy for this disease.
Fig. 2 Comparasion of the time of local control in both
treatment groups
Fig. 3 Comparasion of PFS in both treatment groups
Yu et al. BMC Cancer  (2015) 15:656 Page 5 of 6
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
XY and JL performed the study. XL performed statistical analysis. JH
conceived the study. All authors read and approved the final manuscript.
Acknowledgements
We thank the patients enrolled in this study.
Received: 10 July 2015 Accepted: 27 September 2015
References
1. Wagner TD, Yang GY. The role of chemotherapy and radiation in the
treatment of locally advanced non-small cell lung cancer (NSCLC).
Curr Drug Targets. 2010;11:67–73.
2. Ramlau R, Gorbunova V, Ciuleanu TE, Novello S, Ozguroglu M, Goksel T,
et al. Aflibercept and Docetaxel versus Docetaxel alone after platinum
failure in patients with advanced or metastatic non-small-cell lung cancer: a
randomized, controlled phase III trial. J Clin Oncol. 2012;30:3640–7.
3. Lerouge D, Rivière A, Dansin E, Chouaid C, Dujon C, Schott R, et al. A phase
II study of cisplatin with intravenous and oral vinorelbine as induction
chemotherapy followed by concomitant chemoradiotherapy with oral
vinorelbine and cisplatin for locally advanced non-small cell lung cancer.
BMC Cancer. 2014;14:231.
4. Kim M, Lee J, Ha B, Lee R, Lee KJ, Suh HS. Factors predicting radiation
pneumonitis in locally advanced non-small cell lung cancer. Radiat Oncol J.
2011;29:181–90.
5. Fleischman EH, Kagan AR, Streeter OE, Tyrell J, Wollin M, Leagre CA, et al.
Iodine125 interstitial brachytherapy in the treatment of carcinoma of the
lung. J Surg Oncol. 1992;49:25–8.
6. Wang ZM, Lu J, Liu T, Chen KM, Huang G, Liu FJ. CT-guided interstitial
brachytherapy of inoperable non-small cell lung cancer. Lung Cancer.
2011;74:253–7.
7. Chen HH, Jia RF, Yu L, Zhao MJ, Shao CL, Cheng WY. Bystander effects
induced by continuous
low-dose-rate 125I seeds potentiate the killing action of irradiation on
human lung cancer cells in vitro. Int J Radiat Oncol Biol Phys.
2008;172:1560–6.
8. Martínez-Monge R, Pagola M, Vivas I, López-Picazo JM. CT-guided
permanent brachytherapy for patients with medically inoperable early-stage
non-small cell lung cancer (NSCLC). Lung Cancer. 2008;61:209–13.
9. Fernando HC, Landreneau RJ, Mandrekar SJ, Nichols FC, Hillman SL, Heron
DE, et al. Impact of brachytherapy on local recurrence rates after sublobar
resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial
for high-risk operable non-small-cell lung cancer. J Clin Oncol.
2014;32:2456–62.
10. Cox JD, Stenz J, Pajak TF. Toxicity criteria of the radiation therapy oncology
group (RTOG) and the European organization for research and treatment of
cancer. Int J Radiat Oncol Biol Phys. 1995;31:1341–6.
11. Crvenkova S, Krstevska V. Sequential chemoradiotherapy compared with
concurrent chemoradiotherapy in locally advanced non-small cell lung
cancer: our experience. Prilozi. 2009;30:197–207.
12. Sun Y, Wu YL, Zhou CC, Zhang L, Zhang L, Liu XY et al. Second-line
pemetrexed versus docetaxel in Chinese patients with locally advanced or
metastatic non-small cell lung cancer: A randomized, open-label study.
Lung Cancer. 2013;79:143-50.
13. Huckle A, Al-Qaisieh B, Bownes P. Methods of verifying the output of the
treatment planning system used for high dose rate (HDR) prostate
brachytherapy. Radiother Oncol. 2012;103:261–5.
14. Guckenberger M, Kavanagh A, Partridge M. Combining advanced
radiotherapy technologies to maximize safety and tumor control probability
in stage III non-small cell lung cancer. Strahlenther Onkol. 2012;188:894–900.
15. Chen H, Bao Y, Yu L, Jia R, Cheng W, Shao C. Comparison of cellular
damage response to
low-dose-rate 125I seed irradiation and high-dose-rate gamma irradiation in
human lung cancer cells. Brachytherapy. 2012;11:149–56.
16. Suchorska B, Ruge M, Treuer H, Sturm V, Voges J. Stereotactic brachytherapy
of
low-grade cerebral glioma after tumor resection. Neuro Oncol.
2011;13:1133–42.
17. Zilli T, Boudreau C, Filion EJ, Donath D, Taussky D. Combined intensity-
modulated radiation therapy vs. three-dimensional highly conformal
radiotherapy after (125)I prostate permanent seed brachytherapy: a
comparative treatment planning study. Brachytherapy. 2011;10:416–20.
18. Tran AT, Mandall P, Swindell R, Hoskin PJ, Bottomley DM, Logue JP, et al.
Biochemical outcomes for patients with intermediate risk prostate cancer
treated with I-125 interstitial brachytherapy monotherapy. Radiother Oncol.
2013;109:235–40.
19. Zhu L, Jiang Y, Wang J, Ran W, Yuan H, Liu C, et al. An investigation of 125I
seed permanent implantation for recurrent carcinoma in the head and neck
after surgery and external beam radiotherapy. World J Surg Oncol.
2013;11:60.
20. Machtay M, Paulus R, Moughan J, Komaki R, Bradley JE, Choy H, et al.
Defining local-regional control and its importance in locally advanced non-
small cell lung carcinoma. J Thorac Oncol. 2012;7:716–22.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Yu et al. BMC Cancer  (2015) 15:656 Page 6 of 6
